clinical trial · NCT04218851
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
Merck Sharp & Dohme LLC·phase2·completed·n = 31
Invasive AspergillosisPosaconazole IVPosaconazole PFSPosaconazole tablet
brief summary
This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to \<18 years of age with invasive aspergillosis (IA).
started
Jul 2, 2020
primary completion
Dec 18, 2023
completion
Dec 18, 2023
last updated
Jan 14, 2025
official title
A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to Less Than 18 Years With Invasive Aspergillosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol